UBS’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

UBS’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$3.28M	Buy	260,172 +206,297	+383%	+$2M	﹤0.01%	2439
2014 Q2	$544K	Buy	53,875 +42,041	+355%	+$406K	﹤0.01%	4152
2014 Q1	$159K	Buy	+11,834	New	+$167K	﹤0.01%	5456

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

UBS's CNCE Position: Q3 2014 in Review

UBS increased its Concert Pharmaceuticals, Inc. (CNCE) stake by 383% in Q3 2014, buying an estimated $2M and bringing the position to 260,172 shares worth $3.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2439.

UBS first reported a position in CNCE in Q1 2014 and has held it in 3 quarters since. 51 funds tracked by Wall St. Rank hold CNCE as of Q3 2014.

UBS held 260,172 shares of Concert Pharmaceuticals, Inc. worth $3.28M as of Q3 2014.
UBS bought 206,297 Concert Pharmaceuticals, Inc. shares in Q3 2014, an estimated $2M.
Concert Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2439 holding.
UBS first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and has held it in 3 quarters since.
51 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.